Each year, CiteAb recognizes several companies and individuals for their excellence in the research antibody market. This year, the Lifetime Achievement Award has been awarded to Bio-Techne’s own, Karen Padgett. Join us in congratulating her for her dedication and drive she brings to this business.
Karen started Novus Biologicals in the summer of 1996 to be a company that licenses, produces and markets antibodies for niche and emerging areas of research. She successfully ran Novus Biologicals with consistent growth for 18 years out of Littleton, CO. She sold Novus
Karen Padgett, Vice President of the Antibody Business Unit and Digital Marketing with Bio-Techne
to Bio-Techne in July 2014 to become one of the brands, which greatly expanded the antibody portfolio for customers working in tandem with R&D Systems brand. Karen continues her commitment to her work as the Vice President of the Antibody Business Unit and Digital Marketing with Bio-Techne.
Here is what Dr. Andrew Chalmers, founder of CiteAb has to say about Karen Padgett:
“Karen is widely respected and well-liked by her industry peers, not an easy feat for any individual while also generating positive commercial growth year-on-year. She is a very deserving winner of this prestigious award and along with my colleagues at CiteAb I wish her many congratulations.”
Her contributions go beyond the Bio-Techne walls. A powerful advocate for improving antibody validation standards, she promotes initiatives such as Affinity Binder Knockdown Initiative, the 2nd International Antibody Validation Meeting held in 2016, and The Science Exchange Cancer Biology Reproducibility Project.
Bio-Techne is proud to have Karen leading our teams to promote quality and innovation in the research antibody market. She is well-deserving of this honor. See more about the award on the CiteAb Awards Webpage.